Clinical Trial of a Rapidly Cycling, Non-Cross Reactive Regimen of Approved Therapeutic Agents to Treat Prostate Cancer

Next Previous
Trial Profile

Clinical Trial of a Rapidly Cycling, Non-Cross Reactive Regimen of Approved Therapeutic Agents to Treat Prostate Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Abiraterone acetate (Primary) ; Cabazitaxel (Primary) ; Carboplatin (Primary) ; Enzalutamide (Primary) ; Prednisone (Primary) ; Radium 223 chloride (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms PRINT

    • Most Recent Events

    • 10 Oct 2017 Status changed from not yet recruiting to recruiting.
    • 10 Jun 2017 Biomarkers information updated
    • 28 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top